Han Yanqi, Hua Minghui, Huang Malan, Li Jin, Cheng Shixiong, Wei Xihang
School of Business, Hubei University, Wuhan, China.
Front Psychol. 2023 Mar 9;14:1100717. doi: 10.3389/fpsyg.2023.1100717. eCollection 2023.
This study investigates the present situation of and changing trend in the innovation efficiency of health industry enterprises in China. Based on panel data for 192 listed health companies in China from 2015 to 2020, we analyse innovation efficiency using the DEA-Malmquist index and test convergence using σ-convergence and β-convergence models. From 2016 to 2019, comprehensive average innovation efficiency increased from 0.6207 to 0.7220 and average innovation efficiency decreased significantly in 2020. The average Malmquist index was 1.072. Innovation efficiency in China as a whole, North China, South China, and Northwest China showed σ-convergence. Except for the Northwest region, absolute β-convergence was evident, and in China as a whole, North China, Northeast China, East China, and South China, conditional β-convergence was evident. Overall innovation efficiency of these companies has increased annually but needs further improvement, and the COVID-19 pandemic has had a great negative impact on it. Innovation efficiency and trends in it vary across regions. Furthermore, we should pay attention to the impacts of innovation infrastructure and government scientific and technological support on innovation efficiency.
本研究考察了中国健康产业企业创新效率的现状及变化趋势。基于2015年至2020年中国192家上市健康公司的面板数据,我们使用DEA-Malmquist指数分析创新效率,并使用σ收敛和β收敛模型检验收敛性。2016年至2019年,综合平均创新效率从0.6207提高到0.7220,2020年平均创新效率显著下降。平均Malmquist指数为1.072。中国整体、华北、华南和西北地区的创新效率呈现σ收敛。除西北地区外,绝对β收敛明显,在中国整体、华北、东北、华东和华南地区,条件β收敛明显。这些公司的整体创新效率逐年提高,但仍需进一步提升,且新冠疫情对其产生了重大负面影响。创新效率及其趋势在不同地区存在差异。此外,我们应关注创新基础设施和政府科技支持对创新效率的影响。